Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients
Study Details
Study Description
Brief Summary
A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Individuals diagnosed for COVID-19
|
Outcome Measures
Primary Outcome Measures
- Anosmia [45 days]
Prevalence for anosmia in the COVID-19 + patients
- Ageusia [45 days]
Prevalence for ageusia in the COVID-19 + patients
- Duration of the loss of anosmia ageusia [45 days]
Duration measured in days
Eligibility Criteria
Criteria
Inclusion Criteria:
- COVID-19 diagnosed
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | CHU de Nice | Nice | France |
Sponsors and Collaborators
- Centre Hospitalier Universitaire de Nice
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 20odontocovid01